Chemotherapy-Related Toxicities In Ovarian Cancer Patients
NCT ID: NCT00508378
Last Updated: 2020-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
288 participants
OBSERVATIONAL
2001-01-31
2020-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To assess the preferences of women with ovarian cancer, their clinical caregivers, familial caregivers, and a control group for toxicities associated with chemotherapy.
* To compare preferences of women with ovarian cancer to preferences of their clinical caregivers.
* To compare preferences of women with ovarian cancer to preferences of their familial caregivers.
* To compare preferences of women with ovarian cancer to preferences of a women in the control group.
2. To prospectively collect quality of life data from women with ovarian cancer.
3. To prospectively collect symptom assessment data from women with ovarian cancer.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will also be given quality of life and symptom assessment questionnaires. The questionnaires are simple to read and quick to answer. The questionnaire takes about 15 minutes to complete.
The participant's involvement in this study is limited to the questionnaire/interview. Once that is done, the participant is finished with the study.
This is an investigational study. A total of 288 people will take part in this study. All will be enrolled at M. D. Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interview & Questionnaires
Interview
Interview regarding side-effects of chemotherapy, 30-45 minutes.
Questionnaire
Quality of life survey and symptom assessment questionnaire, 15 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interview
Interview regarding side-effects of chemotherapy, 30-45 minutes.
Questionnaire
Quality of life survey and symptom assessment questionnaire, 15 minutes.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Women with a history of epithelial ovarian cancer presenting to the UTMDACC Gynecologic Oncology Clinic who are seen in follow-up
3. Women who are at least 18 years of age
4. Women who speak English
5. Clinical caregivers of patients with ovarian cancer (UTMDACC gynecologic oncologists, UTMDACC gynecologic medical oncologists, UTMDACC registered nurses and licensed vocational nurses in the UTMDACC Gynecology Clinic, and UTMDACC gynecologic oncology fellows and residents)
6. Familial caregivers of patients with ovarian cancer (primary caregiver)
Exclusion Criteria
2. Participants who are less than 18 years of age
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diane C. Bodurka, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GYN00-409
Identifier Type: -
Identifier Source: org_study_id